The OHRI is a not-for-profit corporation governed by a Board of Directors that includes members of the University of Ottawa, The Ottawa Hospital, The Ottawa Hospital Foundation and the community.
Board Chair
- Ken Newport, Biotech Entrepreneur
Board Vice-Chair and Treasurer
- Ian Mumford, Chief Operating Officer, Canadian Blood Services
Board of Directors
- Dr. Jacques Bradwejn, Dean, Faculty of Medicine, University of Ottawa
- Ian Curry, President and CEO, DNA Genotek
- Gary Hannah, President and CEO , Vocantas
- Don Hewson, President and CEO, HBS Marketing
- Dr. Jack Kitts, President and CEO, The Ottawa Hospital
- Louis Lamontagne, President and CEO, LTL Global Innovations and Management
- Rose Lipiec, Financial Planner, TD Waterhouse Financial Planning
- Randall Marusyk, Managing Partner, MBM Intellectual Property Law
- Dr. Mona Nemer, Vice-President, Research, University of Ottawa
- Dr. Denis Prud’homme, Dean Faculty of Health Sciences, University of Ottawa
- Dr. Duncan Stewart, CEO and Scientific Director, Ottawa Hospital Research Institute, Vice-President of Research, The Ottawa Hospital and Professor of Medicine, University of Ottawa
- Bashir Surani, Member of The Ottawa Hospital Board of Governors
- D. Lynne Watt, Partner, Gowling Lafleur Henderson LLP
- Shirley Westeinde, Chair, Westeinde Group of Companies
Senior Management Team
The OHRI’s senior management team provides scientific and administrative leadership.
- Dr. Duncan Stewart, CEO and Scientific Director
- Dr. Jay Baltz, Associate Scientific Director, Trainees
- Dr. Dean Fergusson, Program Director, Clinical Epidemiology
- Dr. Antoine Hakim, Program Director, Neuroscience
- Robert Hanlon, Chief Operating Officer
- Dr. Rashmi Kothary, Associate Scientific Director
- Dr. Michael McBurney, Program Director, Cancer Therapeutics
- Dr. Leo Renaud, Associate Scientific Director
- Dr. Michael Rudnicki, Program Director, Regenerative Medicine
- Dr. Alexander Sorisky, Program Director, Chronic Disease
- Dr. Valerie Wallace, Program Director, Vision